Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Optimizing drug dosage is crucial for balancing efficacy and safety in cancer treatment.
• Chronic phase chronic myeloid leukemia (CML) patients often require dose adjustments for tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

• To compare the safety and efficacy of two olverembatinib doses (40 mg QOD vs. 30 mg QOD) in TKI-refractory CML patients.
• To determine if a reduced starting dose of olverembatinib improves patient tolerability and treatment adherence.

Main Methods:

• Multi-center retrospective study design.
• Propensity score matching (PSM) to adjust for baseline co-variates between cohorts.
• Comparison of cytogenetic/molecular responses, outcomes, dose adherence, and adverse event rates between 40 mg and 30 mg olverembatinib groups.

Main Results:

• No significant differences in cytogenetic or molecular responses between the 40 mg and 30 mg QOD olverembatinib dose groups.
• Higher proportion of patients maintained the original 30 mg QOD dose at last follow-up compared to the 40 mg QOD dose (64% vs. 44%).
• Significantly lower rates of dose reduction or permanent discontinuation due to adverse events in the 30 mg QOD cohort (21% vs. 41%).

Conclusions:

• Olverembatinib 30 mg QOD is a viable alternative starting dose for chronic phase CML patients refractory to other TKIs.
• The 30 mg QOD starting dose demonstrates comparable efficacy to 40 mg QOD but with improved tolerability and adherence.
• Dose optimization of olverembatinib can enhance patient management in TKI-refractory CML.